{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:04:47Z","timestamp":1793243087438,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013607","name":"American College of Clinical Pharmacy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013607","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaacap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jaac.2025.12.006","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T04:24:10Z","timestamp":1766118250000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Trends in Psychotropic Medication Use, Polypharmacy, and Potential Major Drug\u2013Drug Interactions Among US Youth"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8095-2965","authenticated-orcid":false,"given":"Lin-Chieh","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8312-951X","authenticated-orcid":false,"given":"Molly","family":"Candon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8240-820X","authenticated-orcid":false,"given":"David S.","family":"Mandell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Hennessy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaac.2025.12.006_bib1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S2215-0366(23)00345-0","article-title":"Psychopharmacology in children and adolescents: unmet needs and opportunities","volume":"11","author":"Cortese","year":"2024","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2025.12.006_bib2","article-title":"Trends and prevalence of psychotropic medication use in children and adolescents in the period between 2013 and 2023: a systematic review","volume":"16","author":"Altuwairqi","year":"2024","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.jaac.2025.12.006_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/wps.20881","article-title":"Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review","volume":"20","author":"Correll","year":"2021","journal-title":"World Psychiatry"},{"issue":"4","key":"10.1016\/j.jaac.2025.12.006_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1089\/cap.2022.0092","article-title":"Psychotropic medication prescribing: youth in foster care compared with other medicaid enrollees","volume":"33","author":"Keefe","year":"2023","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jaac.2025.12.006_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.56404","article-title":"Psychotropic polypharmacy among youths enrolled in Medicaid","volume":"7","author":"Chiang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaac.2025.12.006_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.644741","article-title":"Psychotropic polypharmacy in the US pediatric population: a methodologic critique and commentary","volume":"12","author":"Zito","year":"2021","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.jaac.2025.12.006_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115006","article-title":"The mechanisms of interactions of psychotropic drugs with liver and brain cytochrome P450 and their significance for drug effect and drug\u2013drug interactions","volume":"199","author":"Daniel","year":"2022","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.jaac.2025.12.006_bib8","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-063506","article-title":"Major drug\u2013drug interaction exposure among medicaid-insured children in the outpatient setting","volume":"153","author":"Kyler","year":"2024","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jaac.2025.12.006_bib9","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-1042","article-title":"Prescription medication use among children and adolescents in the United States","volume":"142","author":"Qato","year":"2018","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.jaac.2025.12.006_bib10","first-page":"1","article-title":"Antipsychotics and the risks of sudden cardiac death and all-cause death: cohort studies in Medicaid and dually-eligible Medicaid\u2013Medicare beneficiaries of five states","author":"Leonard","year":"2013","journal-title":"J Clin Exp Cardiol"},{"issue":"1","key":"10.1016\/j.jaac.2025.12.006_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psym.2012.11.001","article-title":"QTc prolongation, torsades de pointes, and psychotropic medications","volume":"54","author":"Beach","year":"2013","journal-title":"Psychosomatics"},{"issue":"11","key":"10.1016\/j.jaac.2025.12.006_bib12","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1176\/appi.ps.201300410","article-title":"Trends in psychotropic polypharmacy among youths enrolled in Ohio Medicaid, 2002-2008","volume":"65","author":"Fontanella","year":"2014","journal-title":"Psychiatr Serv"},{"issue":"8","key":"10.1016\/j.jaac.2025.12.006_bib13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1176\/appi.ps.201700260","article-title":"Prevalence, time trends, and utilization patterns of psychotropic polypharmacy among pediatric Medicaid beneficiaries, 1999-2010","volume":"69","author":"Soria Saucedo","year":"2018","journal-title":"Psychiatr Serv"},{"issue":"1","key":"10.1016\/j.jaac.2025.12.006_bib14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/08039488.2022.2042597","article-title":"Polypharmacy in children and adolescents initiating antipsychotic drug in 2008-2016: a nationwide register study","volume":"77","author":"Varimo","year":"2023","journal-title":"Nord J Psychiatry"},{"issue":"8","key":"10.1016\/j.jaac.2025.12.006_bib15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00787-018-01269-2","article-title":"Antidepressant prescription patterns and CNS polypharmacy with antidepressants among children, adolescents, and young adults: a population-based study in Sweden","volume":"28","author":"Lagerberg","year":"2019","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"173","key":"10.1016\/j.jaac.2025.12.006_bib16","first-page":"1","article-title":"National Health and Nutrition Examination Survey: California and Los Angeles County, estimation methods and analytic considerations, 1999-2006 and 2007-2014","author":"Parker","year":"2017","journal-title":"Vital Health Stat 2"},{"issue":"184","key":"10.1016\/j.jaac.2025.12.006_bib17","first-page":"1","article-title":"National Health and Nutrition Examination Survey, 2015-2018: sample design and estimation procedures","volume":"2","author":"Chen","year":"2020","journal-title":"Vital Health Stat"},{"issue":"190","key":"10.1016\/j.jaac.2025.12.006_bib18","first-page":"1","article-title":"National Health and Nutrition Examination Survey, 2017-March 2020 prepandemic file: sample design, estimation, and analytic guidelines","volume":"1","author":"Akinbami","year":"2022","journal-title":"Vital Health Stat"},{"issue":"3","key":"10.1016\/j.jaac.2025.12.006_bib21","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1542\/peds.2007-0984","article-title":"Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders","volume":"121","author":"Mandell","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaac.2025.12.006_bib22","series-title":"Principles in using psychotropic medication in children and adolescents","author":"Lorberg","year":"2019"},{"issue":"11","key":"10.1016\/j.jaac.2025.12.006_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206100","article-title":"Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016","volume":"13","author":"Piper","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jaac.2025.12.006_bib24","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-064245","article-title":"Antidepressant dispensing to US adolescents and young adults: 2016-2022","volume":"153","author":"Chua","year":"2024","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.jaac.2025.12.006_bib25","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S2215-0366(21)00292-3","article-title":"Psychotropic medicine consumption in 65 countries and regions, 2008-19: a longitudinal study","volume":"8","author":"Brauer","year":"2021","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2025.12.006_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/cap.2017.0077","article-title":"National patterns of commonly prescribed psychotropic medications to young people","volume":"28","author":"Sultan","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"10.1016\/j.jaac.2025.12.006_bib27","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2024-068558","article-title":"Prescription stimulant dispensing to US children: 2017-2023","volume":"155","author":"He","year":"2025","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.jaac.2025.12.006_bib28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00787-024-02530-7","article-title":"Recent trends in psychotropic medication use in children and adolescents in Ireland","volume":"34","author":"Parkin","year":"2025","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"4","key":"10.1016\/j.jaac.2025.12.006_bib29","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-0811","article-title":"Prevalence and trends of developmental disabilities among children in the United States: 2009-2017","volume":"144","author":"Zablotsky","year":"2019","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.jaac.2025.12.006_bib30","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-2005","article-title":"Increasing prevalence of developmental disabilities among children in the US: a sign of progress?","volume":"144","author":"Durkin","year":"2019","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.jaac.2025.12.006_bib31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S1071-9091(98)80020-X","article-title":"Benefits of early intervention for children with developmental disabilities","volume":"5","author":"Majnemer","year":"1998","journal-title":"Semin Pediatr Neurol"},{"issue":"8","key":"10.1016\/j.jaac.2025.12.006_bib32","article-title":"Atypical antipsychotics for disruptive behaviour disorders in children and youths","volume":"8","author":"Loy","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.jaac.2025.12.006_bib33","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","article-title":"Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence","volume":"159","author":"Aman","year":"2002","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.jaac.2025.12.006_bib34","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1176\/appi.ps.20240113","article-title":"Psychotropic polypharmacy combinations and duration of polypharmacy among Medicaid-Enrolled youths","volume":"76","author":"Chiang","year":"2025","journal-title":"Psychiatr Serv"},{"issue":"3","key":"10.1016\/j.jaac.2025.12.006_bib35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/cap.2020.0162","article-title":"Polypharmacy in the management of attention-deficit\/hyperactivity disorder in children and adolescents: a review and update","volume":"31","author":"Baker","year":"2021","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"1","key":"10.1016\/j.jaac.2025.12.006_bib36","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41380-021-01161-7","article-title":"Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies","volume":"27","author":"Solmi","year":"2022","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.jaac.2025.12.006_bib37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1001\/jamainternmed.2015.6058","article-title":"Association of off-label drug use and adverse drug events in an adult population","volume":"176","author":"Eguale","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.jaac.2025.12.006_bib38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/070674371506000203","volume":"60","author":"Pringsheim","year":"2015","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.jaac.2025.12.006_bib39","author":"Findling"},{"issue":"9","key":"10.1016\/j.jaac.2025.12.006_bib40","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/j.clinthera.2022.07.011","article-title":"Pediatric off-label antipsychotic use for attention-deficit\/hyperactivity disorder","volume":"44","author":"Lee","year":"2022","journal-title":"Clin Ther"},{"issue":"7","key":"10.1016\/j.jaac.2025.12.006_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.7850","article-title":"Antipsychotic treatment among youths with attention-deficit\/hyperactivity disorder","volume":"2","author":"Sultan","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.jaac.2025.12.006_bib42","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","article-title":"Treatment of young people with antipsychotic medications in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.jaac.2025.12.006_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/pnp.429","article-title":"Antidepressant drug interactions: evidence and clinical significance","volume":"20","author":"Bleakley","year":"2016","journal-title":"Prog Neurol Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.jaac.2025.12.006_bib44","first-page":"S175","article-title":"Pediatric drug\u2013drug interaction evaluation: drug, patient population, and methodological considerations","volume":"61","author":"Gonzalez","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.jaac.2025.12.006_bib45","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1111\/bcp.15341","article-title":"Similarity and consistency assessment of three major online drug\u2013drug interaction resources","volume":"88","author":"Kontsioti","year":"2022","journal-title":"Br J Clin Pharmacol"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089085672502235X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089085672502235X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:35:00Z","timestamp":1793115300000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089085672502235X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":43,"alternative-id":["S089085672502235X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2025.12.006","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in Psychotropic Medication Use, Polypharmacy, and Potential Major Drug\u2013Drug Interactions Among US Youth","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2025.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92025 American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}